Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Ketamine for Depression and Anxiety in Cancer
NCT01680172Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Aug 2012
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) and anxiety disorder comparing Ketamine with Placebo (2 arms). Primary endpoints: Hospital Anxiety and Depression Scale - Anxiety and Hospital Anxiety and Depression Scale - Depression. Started Aug 2012; status: terminated.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on NCT01680172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01680172.